Saturday 17 January 2026
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • Global Fund gets $900M from USA; Islamic Development Bank link up over malaria

Global Fund gets $900M from USA; Islamic Development Bank link up over malaria

23 March 2009

The Global Fund to Fight AIDS, Tuberculosis and Malaria has welcomed the announcement by the US government that it will contribute $900.0 million  for 2009. It is the largest contribution ever made by any country to  the Global Fund since its inception in 2002, $60.0 million above the US  grant for the previous year, bringing the country's total financing for  the agency to over $4.4 billion.

The Global Fund has received contributions from 50 donor countries to  date, in addition to a number of private foundations, corporations and  individuals. Michel Kazatchkine, the Fund's executive director, said:  "it underscores the need to maintain the progress and continue to invest  in people's health globally."

At the end of 2008, Global Fund-supported programs are claimed to have  "averted more than 3.5 million deaths by providing AIDS treatment for  two million people, anti-tuberculosis treatment for 4.6 million people  and by distributing 70 million insecticide-treated bed nets for the  prevention of malaria worldwide." The Fund has so far approved schemes  in 140 countries worth $15.0 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news






Today's issue

EC approves Aspaveli for C3G and primary IC-MPGN
Biotechnology
EC approves Aspaveli for C3G and primary IC-MPGN
16 January 2026
Biotechnology
Chinese CDMO seeks to consolidate leadership in ADC space
16 January 2026
Pharmaceutical
Russian customers forced to save on drug purchases as crisis deepens
16 January 2026
Biotechnology
EC authorization for Waskyra for Wiskott-Aldrich syndrome
16 January 2026
Pharmaceutical
Reported delays to FDA reviews under new fast-track program
16 January 2026
Generics
STADA’s Frank Staud takes on additional role as head of global government affairs
16 January 2026
Pharmaceutical
Avid Bioservices taps new CBO as it leans into growth
16 January 2026

Company Spotlight

Alloy Therapeutics
A privately held biotechnology platform company based in the Boston, Massachusetts area. It operates as a partner-facing “ecosystem” business supporting biologics discovery and development across multiple modalities, and it also participates in company creation through its venture studio model.




The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom


  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising
  • Company News Directory


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin
Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze